EUVIMEDEUVIMED entdecken
Crossref

First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis

Jianying Lei, Jiahao Zhang, Caicong You, Maobai Liu, Na Li

Value in Health · 2024

DOI: 10.1016/j.jval.2024.07.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2024. Verfasst von Jianying Lei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China; The School of Pharmacy, Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Uterine Cervical Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: The BETAcc clinical trial demonstrated that chemotherapy combined with bevacizumab plus atezolizumab (CBA) significantly prolonged progression-free survival and overall survival in patients with metastatic, persistent, or recurrent cervical cancer. However, to the best of our knowledge, the economic value of using this new therapy for this indication is currently unknown. Therefore, our study aimed to evaluate the cost-effectiveness of CBA for the first-line treatment of metastatic, persistent, or recurrent cervical cancer from the United States healthcare payers perspective. METHODS: A state-transition Markov model over a 10-year lifetime horizon was developed to compare the cost and effectiveness of CBA with that of chemotherapy plus bevacizumab (CB). The primary outcomes of our study included costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. One-way sensitivity analysis and probabilistic sensitivity analysis were performed to assess the robustness of the results. RESULTS: CBA was associated with an additional 0.58 QALY at an extra cost of $172 495.90 compared with CB. The incremental cost-effectiveness ratio was $295 972.43/QALY, significantly higher than the willingness-to-pay threshold value of $150 000/QALY. One-way sensitivity analyses revealed that results were most sensitive to the progression-free disease utility, the unit cost of atezolizumab, and progressed disease utility. Probabilistic sensitivity analysis indicated that CBA achieved a 4.3% probability of cost-effectiveness at a $150 000/QALY threshold. To achieve cost-effectiveness, the unit price of atezolizumab must be reduced by approximately 56.6%. CONCLUSIONS: CBA treatment is unlikely to be a cost-effective option compared with CB for patients with persistent, recurrent, or metastatic cervical cancer in the United States.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisUterine Cervical NeoplasmsBevacizumabAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsQuality-Adjusted Life YearsMarkov ChainsNeoplasm Recurrence, LocalHumansFemaleUnited StatesProgression-Free SurvivalNeoplasm MetastasisCost-Effectiveness Analysis

Stichwörter der Autor:innen

BEATcc trialatezolizumabbevacizumabcervical cancercost-effectiveness

Substanzen

BevacizumabatezolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China; The School of Pharmacy, Fujian Medical University, Fuzhou, China.
  • Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, China; The School of Pharmacy, Fujian Medical University, Fuzhou, China. Electronic address: fjxhlina1983@fjmu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Lei, J., Zhang, J., You, C., Liu, M., & Li, N. (2024). First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis. Value in Health. https://doi.org/10.1016/j.jval.2024.07.013

Vancouver

Lei J, Zhang J, You C, Liu M, Li N. First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis. Value in Health. 2024. doi:10.1016/j.jval.2024.07.013

BibTeX
@article{Lei2024,
  author = {Lei, Jianying and Zhang, Jiahao and You, Caicong and Liu, Maobai and Li, Na},
  title = {First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis},
  journal = {Value in Health},
  year = {2024},
  doi = {10.1016/j.jval.2024.07.013}
}
Kostenlos starten →